In vitro antibacterial activity and ferric reducing antioxidant power of selected metal complexes with schiff bases derived from 2,2-dihydroxyinddane-1,3- dione and selected amino acids
DOI:
https://doi.org/10.5457/ams.v50i1-2.578Keywords:
organometallic compound, bioactivity, antibacterial agents, FRAPAbstract
Research into the use of organometallic compounds as potential drugs is extremely popular and yields promising results. In this research, a group of organometallic compounds based on 2,2-dihydroxyindane-1,3-dione and selected amino acids (histidine and phenylalanine) was synthesized. FTIR and UV/VIS spectroscopy were used for structural characterization. Antimicrobial activity was examined by diffusion technique on reference bacterial strains from the ATCC collection. The reduction ability of the complex was examined by the FRAP method. The complexes showed significant inhibitory activity against gram-positive bacteria, with zones of inhibition ranging from 10-25 mm. Antioxidant capacity is also high, with FRAP values ranging from 1315.07-22038.7 µmol/L. These results indicate the potential of the synthesized complexes to be used as antibiotics and synthetic antioxidants. However, additional in vitro and in vivo studies are needed to determine their biological activity in more detail.
Downloads
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
